|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| West Nile Virus | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Encephalitis | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Central Nervous System Infections | |||||
| Central Nervous System Viral Diseases | |||||
| Nervous System Diseases | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Omr-lgG-am | |||||
| Polygam S/D | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Immunoglobulin G | |||||
| Immunoglobulins | |||||
| Immunoglobulins, Intravenous | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||